EZH2 and neoplasm: As shown in Figure 5a, SHR2554 exerted strong tumor suppressive activity in EZH2 mutant xenograft models SU-DHL-6 and PDX002, with TGI of 50% and 41% when 60 mg/kg agent was given by gavage twice a day.